Researchers are rapidly focused on retatrutide, a novel medication developed by Eli Lilly, as a potential advance in body reduction . Different than many previous approaches, retatrutide is a double -action agonist targeting equally GLP-1 and GIP, chemicals that affect hunger and blood glucose re… Read More